- Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
- Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
- Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
- Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
- Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
- Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
- Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
- Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
- Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
More ▼
Key statistics
On Wednesday, Catalyst Pharmaceuticals Inc (CPRX:NAQ) closed at 16.00, -12.18% below its 52-week high of 18.22, set on Apr 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.70 |
---|---|
High | 16.06 |
Low | 15.62 |
Bid | 15.63 |
Offer | 16.39 |
Previous close | 15.54 |
Average volume | 962.85k |
---|---|
Shares outstanding | 118.01m |
Free float | 110.68m |
P/E (TTM) | 25.51 |
Market cap | 1.83bn USD |
EPS (TTM) | 0.6092 USD |
Data delayed at least 15 minutes, as of Apr 17 2024 21:00 BST.
More ▼